Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Non-Current Debt (2017 - 2019)

AC Immune (ACIU) reported Non-Current Debt of $301440.6 for Q3 2019, up 117968.07% on a QoQ basis from $255.31 in Q2 2019.

AC Immune (ACIU) has 3 years of Non-Current Debt data on file, last reported at $301440.6 in Q3 2019.

  • Quarterly Non-Current Debt changed N/A year-over-year to $301440.6 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $301440.6 (changed N/A YoY) and the FY2018 annual result came in at $186899.3, down 62.67% from the prior year.
  • Non-Current Debt improved to $301440.6 in Q3 2019 per ACIU's latest filing, from $255.31 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $500708.2 in Q4 2017 and bottomed at $255.31 in Q2 2019.
  • The 3-year median for Non-Current Debt is $196427.9 (2017), against an average of $229068.6.
  • Peak annual rise in Non-Current Debt reached 62.67% in 2018, while the deepest fall reached 62.67% in 2018.
  • Tracing ACIU's Non-Current Debt over 3 years: stood at $500708.2 in 2017, then plunged by 62.67% to $186899.3 in 2018, then surged by 61.29% to $301440.6 in 2019.
  • Per Business Quant, the three latest ACIU Non-Current Debt figures stand at $301440.6 (Q3 2019), $255.31 (Q2 2019), and $225914.1 (Q1 2019).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 319.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 105.94 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.99 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 AC Immune 325.88 Mn 211.53 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2019 301,440.55
Sep 30, 2019 301,440.55
Jun 30, 2019 255.31
Jun 30, 2019 255.31
Mar 31, 2019 225,914.07
Mar 31, 2019 225,914.07
Dec 31, 2018 186,899.27
Dec 31, 2018 186,899.27
Dec 31, 2017 500,708.16
Dec 31, 2017 500,708.16
Sep 30, 2017 196,427.87
Sep 30, 2017 196,427.87
Jun 30, 2017 191,834.75
Jun 30, 2017 191,834.75